128 related articles for article (PubMed ID: 23172081)
21. Prognostic factors for osteosarcoma of the extremity treated with neoadjuvant chemotherapy: 15-year experience in 789 patients treated at a single institution.
Bacci G; Longhi A; Versari M; Mercuri M; Briccoli A; Picci P
Cancer; 2006 Mar; 106(5):1154-61. PubMed ID: 16421923
[TBL] [Abstract][Full Text] [Related]
22. Increased expression of membrane-type matrix metalloproteinase-1 is correlated with poor prognosis in patients with osteosarcoma.
Uchibori M; Nishida Y; Nagasaka T; Yamada Y; Nakanishi K; Ishiguro N
Int J Oncol; 2006 Jan; 28(1):33-42. PubMed ID: 16327977
[TBL] [Abstract][Full Text] [Related]
23. KAI-1 expression in pediatric high-grade osteosarcoma.
Leavey PJ; Timmons C; Frawley W; Lombardi D; Ashfaq R
Pediatr Dev Pathol; 2006; 9(3):219-24. PubMed ID: 16944980
[TBL] [Abstract][Full Text] [Related]
24. Expression of platelet-derived growth factor-alpha receptor in human osteosarcoma is not a predictor of outcome.
Sulzbacher I; Birner P; Dominkus M; Pichlhofer B; Mazal PR
Pathology; 2010 Dec; 42(7):664-8. PubMed ID: 21080877
[TBL] [Abstract][Full Text] [Related]
25. Expression of Smad and its signalling cascade in osteosarcoma.
Won KY; Kim YW; Park YK
Pathology; 2010 Apr; 42(3):242-7. PubMed ID: 20350217
[TBL] [Abstract][Full Text] [Related]
26. The expression of CRM1 is associated with prognosis in human osteosarcoma.
Yao Y; Dong Y; Lin F; Zhao H; Shen Z; Chen P; Sun YJ; Tang LN; Zheng SE
Oncol Rep; 2009 Jan; 21(1):229-35. PubMed ID: 19082467
[TBL] [Abstract][Full Text] [Related]
27. Expression of platelet-derived growth factor-AA is associated with tumor progression in osteosarcoma.
Sulzbacher I; Birner P; Trieb K; Träxler M; Lang S; Chott A
Mod Pathol; 2003 Jan; 16(1):66-71. PubMed ID: 12527715
[TBL] [Abstract][Full Text] [Related]
28. Role of integrin-linked kinase in osteosarcoma progression.
Rhee SH; Han I; Lee MR; Cho HS; Oh JH; Kim HS
J Orthop Res; 2013 Oct; 31(10):1668-75. PubMed ID: 23784942
[TBL] [Abstract][Full Text] [Related]
29. Immunoexpression of Ezrin and CD44 in patients with osteosarcoma.
Boldrini E; Peres SV; Morini S; de Camargo B
J Pediatr Hematol Oncol; 2010 Aug; 32(6):e213-7. PubMed ID: 20562647
[TBL] [Abstract][Full Text] [Related]
30. Vascular endothelial growth factor expression in osteosarcoma.
Charity RM; Foukas AF; Deshmukh NS; Grimer RJ
Clin Orthop Relat Res; 2006 Jul; 448():193-8. PubMed ID: 16826116
[TBL] [Abstract][Full Text] [Related]
31. May P-glycoprotein status be used to stratify high-grade osteosarcoma patients? Results from the Italian/Scandinavian Sarcoma Group 1 treatment protocol.
Serra M; Pasello M; Manara MC; Scotlandi K; Ferrari S; Bertoni F; Mercuri M; Alvegard TA; Picci P; Bacci G; Smeland S
Int J Oncol; 2006 Dec; 29(6):1459-68. PubMed ID: 17088985
[TBL] [Abstract][Full Text] [Related]
32. Expression of matrix metalloproteinases-2, -8, -13, -26, and tissue inhibitors of metalloproteinase-1 in human osteosarcoma.
Korpi JT; Hagström J; Lehtonen N; Parkkinen J; Sorsa T; Salo T; Laitinen M
Surg Oncol; 2011 Mar; 20(1):e18-22. PubMed ID: 20880700
[TBL] [Abstract][Full Text] [Related]
33. Comparison of long-term outcome between doublet and triplet neoadjuvant chemotherapy in non-metastatic osteosarcoma of the extremity.
Hong S; Shin SJ; Jung M; Jeong J; Lee YJ; Shin KH; Roh JK; Rha SY
Oncology; 2011; 80(1-2):107-17. PubMed ID: 21677455
[TBL] [Abstract][Full Text] [Related]
34. [Expression and significance of N-cadherin and β-catenin protein in osteosarcoma].
Yang JZ; Zhang XH; Liu JR; Ding Y; Gao F; Wang Y
Zhonghua Zhong Liu Za Zhi; 2010 Aug; 32(8):586-9. PubMed ID: 21122409
[TBL] [Abstract][Full Text] [Related]
35. Vascular endothelial growth factor expression in untreated osteosarcoma is predictive of pulmonary metastasis and poor prognosis.
Kaya M; Wada T; Akatsuka T; Kawaguchi S; Nagoya S; Shindoh M; Higashino F; Mezawa F; Okada F; Ishii S
Clin Cancer Res; 2000 Feb; 6(2):572-7. PubMed ID: 10690541
[TBL] [Abstract][Full Text] [Related]
36. pFAK-Y397 overexpression as both a prognostic and a predictive biomarker for patients with metastatic osteosarcoma.
Thanapprapasr K; Nartthanarung A; Thanapprapasr D; Jinawath A
PLoS One; 2017; 12(8):e0182989. PubMed ID: 28846700
[TBL] [Abstract][Full Text] [Related]
37. Ezrin expression predicts survival in stage IIB osteosarcomas.
Kim MS; Song WS; Cho WH; Lee SY; Jeon DG
Clin Orthop Relat Res; 2007 Jun; 459():229-36. PubMed ID: 17353802
[TBL] [Abstract][Full Text] [Related]
38. Ephrin A4 expression in osteosarcoma, impact on prognosis, and patient outcome.
Abdou AG; Abd el-Wahed MM; Asaad NY; Samaka RM; Abdallaha R
Indian J Cancer; 2010; 47(1):46-52. PubMed ID: 20071790
[TBL] [Abstract][Full Text] [Related]
39. Tissue necrosis after chemotherapy in osteosarcoma as the important prognostic factor.
Sami SH; Rafati AH; Hodjat P
Saudi Med J; 2008 Aug; 29(8):1124-9. PubMed ID: 18690304
[TBL] [Abstract][Full Text] [Related]
40. Grade of chemotherapy-induced necrosis as a predictor of local and systemic control in 881 patients with non-metastatic osteosarcoma of the extremities treated with neoadjuvant chemotherapy in a single institution.
Bacci G; Mercuri M; Longhi A; Ferrari S; Bertoni F; Versari M; Picci P
Eur J Cancer; 2005 Sep; 41(14):2079-85. PubMed ID: 16115755
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
